
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>The Importance of Treatment Timing and Positioning in IBD</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>The Importance of Treatment Timing and Positioning in IBD</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Inflammatory Bowel Diseases, 2025</li><li>- <b>DOI:</b> https://doi.org/10.1093/ibd/izaf282</li><li>- <b>Type:</b> Commentary</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What specific genetic marker significantly increases the risk of developing anti-drug antibodies to infliximab and adalimumab in Crohn's disease patients?</li><li>- What term describes the plateau in treatment efficacy maintained by resistant immune cell populations that persist despite biologic therapy?</li><li>- What are two examples of novel cellular immunotherapies proposed to overcome treatment resistance in IBD?</li><li>- What are the three primary categories of mechanisms contributing to the progressive decline in biologic efficacy in IBD?</li><li>- In which IBD subtype is the impact of delayed or suboptimal biologic intervention more pronounced due to its transmural and fibrotic nature?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Problem:</b> Declining Efficacy of Biologic Therapies</strong></summary>
            <div>
                <ul><li>- Therapeutic efficacy of biologics <u>progressively reduces</u> as patients move from first- to second- and third-line agents.</li><li>- This decline reveals a major limitation in current IBD management: a limited capacity to recapture durable response after biologic failure.</li></ul>
                
        <details>
            <summary><strong>Multifactorial Basis for Loss of Efficacy</strong></summary>
            <div>
                <ul><li>- The decline in response is multifactorial, involving a complex interplay of mechanisms.</li></ul>
                
        <details>
            <summary><strong><b>1. Pharmacologic Mechanisms</b></strong></summary>
            <div>
                <ul><li>- <b>Altered Drug Clearance:</b> Leads to sub-therapeutic trough levels.</li><li>- <b>Contributing Factors:</b> <q>Low serum albumin</q>, high inflammatory burden, and altered body composition can exacerbate poor pharmacokinetics.</li><li>- <b>Solution:</b> <u>Therapeutic Drug Monitoring (TDM)</u> is a valuable tool to identify pharmacokinetic failures and guide personalized dosing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>2. Immunologic Mechanisms</b> (Immunogenicity)</strong></summary>
            <div>
                <ul><li>- Repeated exposure to biologics can trigger the formation of <u><b>anti-drug antibodies (ADAs)</b></u>.</li><li>- ADAs neutralize therapeutic activity and accelerate drug clearance, leading to reduced drug levels and diminished clinical response.</li></ul>
                
        <details>
            <summary><strong>ADA Risk Factors</strong></summary>
            <div>
                <ul><li>- <b>Drug-related:</b> Particularly well-documented for chimeric monoclonal antibodies like <q><b>infliximab</b></q>.</li><li>- <b>Patient-specific:</b> Genetic predisposition and immune burden.</li><li>- <b>Treatment-related:</b> Drug structure, administration route, and concomitant immunosuppressive therapy.</li></ul>
                
        <details>
            <summary><strong>Genetic Predisposition</strong></summary>
            <div>
                <ul><li>- Crohn's disease patients with the <q><u><b>HLA-DQA1*05 aplotype</b></u></q> have a significantly increased risk of developing ADAs against <b>infliximab</b> and <b>adalimumab</b>.</li><li>- For these patients, combination therapy with <q>thiopurines</q> might increase persistence on therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>3. Cellular Mechanisms</b> & Disease Refractoriness</strong></summary>
            <div>
                <ul><li>- Patients requiring multiple biologics often have more aggressive, treatment-resistant phenotypes (e.g., penetrating CD, extensive UC).</li><li>- These phenotypes may harbor molecular determinants of resistance like altered cytokine profiles, genetic polymorphisms, and dysregulated microbiota.</li></ul>
                
        <details>
            <summary><strong><b>Clonal Immune Resistance</b></strong></summary>
            <div>
                <ul><li>- Successive biologic therapies can drive the expansion of resistant immune cell clones (Puca et al.).</li><li>- These clones exhibit features that sustain inflammation despite targeted intervention.</li></ul>
                
        <details>
            <summary><strong>Characteristics of Resistant Clones</strong></summary>
            <div>
                <ul><li>- Downregulated cytokine receptor expression.</li><li>- Resistance to apoptosis.</li><li>- Upregulated <q><b>NF-κB signaling</b></q>.</li><li>- These clones can perpetuate disease through alternative inflammatory pathways.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>The "<b>Therapeutic Ceiling</b>"</strong></summary>
            <div>
                <ul><li>- A concept describing a <u>plateau in treatment efficacy</u> maintained by resistant immune cell populations that persist despite biologic therapy (Neurath et al.).</li><li>- Highlights the limitations of current cytokine blockade strategies.</li></ul>
                
        <details>
            <summary><strong>Overcoming the Ceiling</strong></summary>
            <div>
                <ul><li>- Novel cellular immunotherapies may be necessary to overcome this barrier.</li><li>- <b>Examples:</b> <q>CAR-T cells targeting pathogenic T-cell subsets</q> or <q>regulatory T-cell (Treg) infusions</q>.</li><li>- <b>Goal:</b> Reprogram or eliminate resistant clones.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Analogy to Other Diseases</strong></summary>
            <div>
                <ul><li>- This clonal evolution mirrors patterns seen in <q>oncology and other autoimmune diseases</q>.</li><li>- Selective pressure from targeted therapies drives the emergence of resistant cellular subtypes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Disease-Specific Implications</strong></summary>
            <div>
                <ul><li>- The impact of delayed or suboptimal biologic intervention varies between Crohn's disease and ulcerative colitis.</li></ul>
                
        <details>
            <summary><strong><b>Crohn's Disease (CD)</b></strong></summary>
            <div>
                <ul><li>- Impact of delay is <u>more pronounced</u> than in UC.</li><li>- Due to CD's <q>transmural and fibrotic nature</q>, leading to a tendency for irreversible structural damage.</li><li>- Patients often present with fibrotic or penetrating phenotypes, which are less responsive to cytokine blockade.</li></ul>
                
        <details>
            <summary><strong>Fibrotic Remodeling</strong></summary>
            <div>
                <ul><li>- Chronic inflammation leads to irreversible tissue stiffening.</li><li>- This fibrotic tissue is largely <u>unresponsive</u> to current biologic or small-molecule therapies.</li><li>- Underscores the urgent need for early anti-inflammatory intervention and development of anti-fibrotic therapies.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Ulcerative Colitis (UC)</b></strong></summary>
            <div>
                <ul><li>- <u>Mucosal healing</u> remains a more attainable target, even with later treatment initiation.</li><li>- However, prolonged inflammation still correlates with an increased <q><b>colectomy risk</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Clinical Imperative:</b> Timing & Sequencing</strong></summary>
            <div>
                <ul><li>- Delays in initiating or changing biologic therapy are linked to worse long-term outcomes.</li><li>- <b>Outcomes:</b> Disease progression, hospitalization, and surgical intervention.</li><li>- In contrast, <u>early intervention</u> is associated with better short- and long-term outcomes.</li></ul>
                
        <details>
            <summary><strong>Evidence on Treatment Sequencing</strong></summary>
            <div>
                <ul><li>- Real-world data consistently shows that the durability of biologic response <u>declines sharply</u> beyond the first line of therapy.</li><li>- Treatment duration decreases with each subsequent switch, mainly due to loss of response and immune-mediated cross-resistance.</li></ul>
                
        <details>
            <summary><strong>UK IBD BioResource Study</strong></summary>
            <div>
                <ul><li>- A large-scale analysis of over <q><b>13,000 patients</b></q>.</li><li>- Provided compelling evidence that treatment outcomes are profoundly influenced by the order in which biologics are used.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Strategic Sequencing Recommendations</strong></summary>
            <div>
                <ul><li>- A refined, patient-tailored approach is needed to optimize long-term outcomes.</li></ul>
                
        <details>
            <summary><strong><b>Mechanistic Diversification</b></strong></summary>
            <div>
                <ul><li>- Switching to a biologic or small molecule with a <u>distinct mechanism of action</u> may yield superior outcomes after failure.</li><li>- Cycling within the same therapeutic class (e.g., one anti-TNF to another) may offer <q>limited benefit</q> due to shared resistance pathways.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Role of Small Molecules</b></strong></summary>
            <div>
                <ul><li>- <b>Examples:</b> <q>JAK inhibitors</q> or <q>S1P receptor modulators</q>.</li><li>- Early real-world data suggest they may retain efficacy even after prior biologic exposure.</li><li>- Their performance may be less affected by treatment delay or sequencing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Variability Across Biologic Classes</strong></summary>
            <div>
                <ul><li>- <b>Anti-TNF agents:</b> Showed earlier introduction but <q>higher rates of dose escalation</q>.</li><li>- <b>Newer agents (Vedolizumab, Ustekinumab):</b> Exhibited different persistence profiles.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Future Therapeutic Frameworks</strong></summary>
            <div>
                <ul><li>- Transition from reactive treatment adjustments to <u>proactive, biology-driven</u> therapeutic planning.</li><li>- Integrate molecular predictors of response with clinical decision-making.</li></ul>
                
        <details>
            <summary><strong>Key Components for Future Management</strong></summary>
            <div>
                <ul><li>- Immune profiling</li><li>- Clonal tracking</li><li>- Precision immunotherapy</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Conclusion:</b> Key Takeaways</strong></summary>
            <div>
                <ul><li>- The progressive decline in biologic efficacy reflects both <u>mechanistic resistance</u> and the <u>biological cost of delayed intervention</u>.</li><li>- Prolonged inflammation, fibrosis, and empirical sequencing contribute to cumulative tissue damage and reduced responsiveness.</li></ul>
                
        <details>
            <summary><strong>Recommendations for Future IBD Management</strong></summary>
            <div>
                <ul><li>- <b>Act Early:</b> Integrate early use of biologics or small molecules.</li><li>- <b>Choose Strategically:</b> Use biomarker-guided, mechanism-based sequencing.</li><li>- <b>Anticipate Resistance:</b> Employ tools like Therapeutic Drug Monitoring (TDM).</li><li>- The ultimate message is: "In IBD, <u><b>time is inflammation</b></u>."</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
